ロード中...
Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
Since 2010, six drugs have been approved for the treatment of castration-resistant prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor activator of nuclear factor kappa B...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Molecular Diversity Preservation International (MDPI)
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3742227/ https://ncbi.nlm.nih.gov/pubmed/23880851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms140713958 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|